Announcement • Jul 23
SSY Group Limited Announces Update on Drug Approvals Enhancing Diversified Pharmaceutical Product Portfolio The board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for the following four products from National Medical Products Administration of China, all being under type 4 chemical drug and regarded as passing the consistency evaluation. Hemofiltration Replacement Fluid of Sodium Citrate (5000ml): This product is mainly used as a replacement fluid in continuous renal replacement therapy (CRRT) with local citrate anticoagulation, and is particularly suitable for patients such as those with an increased risk of bleeding who are not advised for systemic anticoagulation with heparin. Compared to clinical mainstream split citrate formula (bicarbonate replacement fluid combined with a separate sodium citrate anticoagulant), this product has significant clinical advantages and a promising market prospect. The Group is actively developing large-volume injections such as hemofiltration replacement solutions and peritoneal dialysis solutions, further improving its product portfolio. Benidipine Hydrochloride Tablets (4mg): This product is mainly used for the treatment of primary hypertension and angina pectoris. The Group has established a comprehensive hypertension product portfolio, covering 2nd and 3rd generation calcium channel blockers, ACE inhibitors, -receptor blockers, and multiple single- tablet compound preparations, along with intravenous emergency antihypertensive drugs used in intensive care unit (ICU). Among which, the Group's Benidipine Hydrochloride Tablets in 8mg specification has been approved for market and selected in the tender result of the eleventh batch of the National Centralised Medicines Procurement. With the approval of its 4mg specification, the initial low-dose treatment needs for hypertension can be fully met, forming a complete dose gradient of "initial titration 4mg + maintenance therapy 8mg". Polyvinyl Alcohol Eye Drops 1.4% (0.4ml: 5.6mg): This product is mainly used as a lubricant for prevention or treatment of irritation symptoms such as dry eyes, foreign matter sensation and eye fatigue, or for improvement of eye dryness symptoms. Polyvinyl Alcohol Eye Drop is in single-dose packaging, preservative-free, and is an OTC product for office workers experiencing eye strain, people spending long time at screens or with sensitive ocular surfaces for their immediate relief of dry eyes. The Group has a strategic layout in ophthalmic drug segment with single-dose and preservative-free formulations, and has built a product portfolio including anti-infectives, anti-allergens, intraocular pressure lowering, artificial tears and ocular anti-inflammatory, forming a dual-channel layout of in-hospital prescription drugs and retail OTC. Fat Emulsion, Amino Acids (17) and Glucose (19%) Injection (1540ml and 1026ml): This product is mainly used for adult patients who are unable, with impaired function or not advised for receiving nutrition orally or enterally. This product is a complex three-chamber bag preparation for parenteral nutrition with high technological barriers. It is mainly used for intravenous nutritional support in adult patients after surgery, those with tumors or in ICU. The newly approved 1540ml and 1026ml specifications can meet the individualised clinical needs of patients with different weights and energy requirements. The Group is systematically developing a parenteral nutrition product platform covering premixed three-chamber bag all-in-one preparations, nutrients, vitamins, trace elements and electrolyte supplements. This approval further enhances the Group's high-end intravenous nutrition product portfolio, creating synergy with its basic infusion, amino acid and fat emulsion series, and will bring a positive effect on its expansion into the perioperative and critical care nutrition markets. Announcement • Jul 21
SSY Group Limited Obtains Approval For Registration Of Gadobutrol As Bulk Drug For Market Preparations SSY Group Limited has announced that the Group’s Gadobutrol has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Gadobutrol is a magnetic resonance imaging contrast agent used for adults and children of all ages (including full-term newborns), and is mainly used for contrast-enhanced magnetic resonance imaging (CE-MRI) examinations of lesions in various parts of the body (including the brain and spinal cord), as well as contrast-enhanced magnetic resonance angiography (CE-MRA) examinations of various parts of the body. Gadobutrol, as a new generation of magnetic resonance imaging contrast agent with macrocyclic structure, is more stable and safer than Gadopentetate Dimeglumine with linear structure, offering advantage for clinical substitution. Gadolinium is a rare-earth metal, and the Group is actively developing an integrated business of bulk drugs and injection preparations under Gadolinium category. Announcement • Jul 18
Ssy Group Limited Obtains Approval for Drug Production and Registration of Choline Fenofibrate Sustained-Release Capsules SSY Group Limited has obtained the approval for drug production and registration for Choline Fenofibrate Sustained-release Capsules (135mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Choline Fenofibrate Sustained-release Capsule is mainly used in adults with controlled diets for lowering triglyceride levels in patients with severe hypertriglyceridemia, and for treatment of patients with primary hypercholesterolemia or mixed dyslipidemia. As compared to traditional fenofibrate, choline fenofibrate has a direct effect, a lower liver and kidney burden, can be taken without dietary restrictions and safely combined with statins drug, making it a high-end triglyceride-lowering product of next generation with clinical necessity. Announcement • Jul 13
SSY Group Limited Obtains Approval for Registration of Baloxavir Marboxil as Bulk Drug in China SSY Group Limited announced that the Group’s Baloxavir Marboxil has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities. Baloxavir Marboxil is mainly used for the treatment of influenza A and influenza B. Announcement • Jun 24
SSY Group Limited Obtains Approval for Drug Production and Registration for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution SSY Group Limited has obtained the approval for drug production and registration for Safinamide Mesylate Tablets (100mg and 50mg) from National Medical Products Administration of China (the NMPA), being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Safinamide Mesylate Tablet is mainly used in combination therapy for adult patients with primary Parkinson’s disease and symptoms fluctuation, in combination with other drugs for Parkinson’s disease such as levodopa. As stated in the Company’s announcement dated 26 May 2026, the Group’s Safinamide Mesylate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Group has obtained the approval for drug production and registration for Procaterol Hydrochloride Inhalation Solution (0.3ml: 30µg) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Procaterol Hydrochloride Inhalation Solution is mainly used in the relief of various symptoms based on airflow limitation in bronchial asthma, chronic bronchitis and emphysema. Announcement • Jun 09
Ssy Group Limited Obtains Approval to Become Market Authorization Holder of Ceftizoxime Sodium for Injection SSY Group Limited has obtained the approval from the National Medical Products Administration of China for the change to become the market authorization holder of Ceftizoxime Sodium for Injection (1g and 0.5g). Ceftizoxime Sodium for Injection is mainly used for the treatment of (1) lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections caused by susceptible bacteria; (2) meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae; and (3) uncomplicated gonorrhea. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Upcoming Dividend • May 13
Upcoming dividend of HK$0.03 per share Eligible shareholders must have bought the stock before 20 May 2026. Payment date: 04 June 2026. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Hong Kong dividend payers (6.7%). Higher than average of industry peers (2.4%). Announcement • Apr 22
Ssy Group Limited Announces Furosemide Obtains Approval for Registration in China The board of directors of SSY Group Limited is announcing that the Group’s Furosemide has obtained the approval for registration from the National Medical Products Administration of China to become bulk drug for the preparations on the market. As stated in the Company’s announcements dated 30 June 2025 and 27 December 2024 respectively, the Group has obtained the approvals for drug production and registration for Furosemide Tablet and Furosemide Injection from the NMPA. Furosemide is mainly used for the treatment of various diseases with edema, hypertension, hyperkalemia and hypercalcemia, dilutional hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and acute drug poisoning (such as barbiturate poisoning), and for the prevention of acute kidney failure. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Price Target Changed • Apr 07
Price target decreased by 8.9% to HK$3.64 Down from HK$3.99, the current price target is an average from 5 analysts. New target price is 45% above last closing price of HK$2.50. Stock is down 17% over the past year. The company is forecast to post earnings per share of HK$0.20 for next year compared to HK$0.16 last year. Major Estimate Revision • Apr 07
Consensus EPS estimates fall by 23% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from HK$0.253 to HK$0.195. Revenue forecast unchanged from HK$4.87b at last update. Net income forecast to grow 25% next year vs 17% growth forecast for Pharmaceuticals industry in Hong Kong. Consensus price target down from HK$3.99 to HK$3.64. Share price was steady at HK$2.50 over the past week. Declared Dividend • Mar 29
Final dividend of HK$0.03 announced Shareholders will receive a dividend of HK$0.03. Ex-date: 20th May 2026 Payment date: 4th June 2026 Dividend yield will be 3.3%, which is lower than the industry average of 3.6%. Sustainability & Growth Dividend is covered by earnings (51% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 19% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 65% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 28
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: HK$0.16 (down from HK$0.36 in FY 2024). Revenue: HK$4.17b (down 28% from FY 2024). Net income: HK$470.6m (down 56% from FY 2024). Profit margin: 11% (down from 18% in FY 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 20% per year. Announcement • Mar 27
SSY Group Limited, Annual General Meeting, May 15, 2026 SSY Group Limited, Annual General Meeting, May 15, 2026, at 14:00 China Standard Time. Location: rooms 4902-03, 49th floor, central plaza, 18 harbour road, wanchai., Hong Kong Announcement • Mar 17
SSY Group Limited to Report Fiscal Year 2025 Results on Mar 27, 2026 SSY Group Limited announced that they will report fiscal year 2025 results on Mar 27, 2026 Announcement • Mar 06
Ssy Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Calcium Levofolinate for Injection (25mg) from National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Calcium Levofolinate for Injection is mainly used for the treatment of gastric cancer and colorectal cancer in combination with 5-fluorouracil. Valuation Update With 7 Day Price Move • Mar 03
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to HK$2.46, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 11x in the Pharmaceuticals industry in Hong Kong. Total loss to shareholders of 38% over the past three years. Announcement • Feb 16
SSY Group Limited Provides Group Earnings Guidance for the Year Ended 31 December 2025 SSY Group Limited provided group earnings guidance for the year ended 31 December 2025. The board of directors of the Company (the "Board") informed shareholders of the Company (the "Shareholders") and potential investors that, based on the information currently available to the Board and after preliminary assessment of the Group's unaudited management accounts for the year ended 31 December 2025, the Board preliminarily estimates that the Group is expected to record a reduction in profit attributable to equity shareholders of the Company for the year ended 31 December 2025 in the range of 45% to 60% as compared to profit attributable to equity shareholders of the Company of HKD 1,061,150,000 for the year ended 31 December 2024. The estimated reduction in the profit attributable to equity shareholders of the Company is mainly attributable to the decline in turnover due to the following factors: the influenza outbreak in the PRC led to strong market demand for intravenous infusion solutions and other medicines in the first quarter of 2024, but the terminal sales volume of medicines has declined due to the absence of large-scale epidemic in the PRC and the control of medical insurance cost throughout the year ended 31 December 2025; the expansion of various forms of volume-based procurement (including the National Centralised Medicines Procurement and local alliance centralised procurement) and the intensification of domestic and international industry competition have brought about continuing price pressure; and turnover of Bromhexine Hydrochloride in ampoule injection decreased as it was no longer sold through National Centralized Medicines Procurement. Announcement • Jan 28
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for adding 2ml specification for Composite Potassium Hydrogen Phosphate Injection from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Composite Pot potassium Hydrogen Phosphate In injection is a compound preparation which is mainly used for correction of hypophosphatemia in adult and child patients and for parenteral nutrition in adult and child patients when enteral nutrition is impossible, insufficient or prohibited. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Announcement • Jan 05
SSY Group Limited Obtains Approval for Drug Production and Registration for Perindopril Arginine and Amlodipine Besylate Tablets (III) The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Perindopril Arginine and Amlodipine Besylate Tablets (III) (perindopril arginine 10mg, amlodipine besylate 5mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Perindopril Arginines and AmlodipineBylate Tablet is a compound preparation which is mainly used in adult patients whose hypertension is not adequately controlled by monotherapy, or as an alternative therapy for primary hypertension which is under control by combination therapy with the same dose level of perindopril and amlodipine. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Announcement • Nov 28
SSY Group Limited Obtains Approval for Drug Production and Registration for Tolterodine Tartrate Sustained-Release Capsules (4mg) The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tolterodine Tartrate Sustained-release Capsules (4mg) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Tolterodine Tartrates Sustained-release Capsule is mainly used for treatment of overactive bladder. Announcement • Oct 20
SSY Group Limited Obtains Approval for Drug Production and Registration for Levlodipine Besilate Tablets The board of directors of SSY Group Limited announced that the Group has obtained the approval s for drug production and registration for Levamlodipine Besilate Tablets (5mg and 2.5mg) from the National Medical Products Administration of China, both being under type 4 chemical drug and regarded as passing the consistency evaluation. Levamlodipine besilate Tablet is mainly used for the treatment of hypertension, chronic stable angina and vasospastic angina, which may be used alone or in combination with other drugs. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Buy Or Sell Opportunity • Sep 08
Now 21% undervalued Over the last 90 days, the stock has risen 7.4% to HK$3.20. The fair value is estimated to be HK$4.04, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.1% over the last 3 years. Earnings per share has declined by 6.1%. Revenue is forecast to grow by 21% in 2 years. Earnings are forecast to grow by 46% in the next 2 years. Major Estimate Revision • Sep 05
Consensus revenue estimates decrease by 15% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from HK$5.87b to HK$4.99b. EPS estimate unchanged from HK$0.29 per share at last update. Pharmaceuticals industry in Hong Kong expected to see average net income growth of 19% next year. Consensus price target down from HK$5.11 to HK$4.21. Share price rose 14% to HK$3.25 over the past week. Announcement • Sep 01
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Allopurinol Tablets (0.1g) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Allopurinol Tablet is mainly used for patients with primary or secondary gout, for patients with leukemia, lymphoma and malignant tumors undergoing treatment, and for the treatment of patients with recurrent calcium oxalate stones. As stated in the Company's announcement dated 28 April 2025, the Group's Allopurinol bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Reported Earnings • Aug 31
First half 2025 earnings released: EPS: HK$0.096 (vs HK$0.23 in 1H 2024) First half 2025 results: EPS: HK$0.096 (down from HK$0.23 in 1H 2024). Revenue: HK$2.15b (down 36% from 1H 2024). Net income: HK$283.5m (down 59% from 1H 2024). Profit margin: 13% (down from 21% in 1H 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 8% per year. Declared Dividend • Aug 30
First half dividend of HK$0.05 announced Shareholders will receive a dividend of HK$0.05. Ex-date: 11th September 2025 Payment date: 26th September 2025 Dividend yield will be 5.1%, which is higher than the industry average of 3.6%. Sustainability & Growth Dividend is covered by earnings (43% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 21% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 83% over the next 3 years, which should provide support to the dividend and adequate earnings cover. New Risk • Aug 29
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 21% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (14% net profit margin). Announcement • Aug 19
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Morinidazole has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Morinidazole is a nitroimidazole antibiotic which is mainly used for the treatment of appendicitis and pelvic inflammatory disease caused by anaerobic bacteria. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Announcement • Aug 18
SSY Group Limited to Report First Half, 2025 Results on Aug 28, 2025 SSY Group Limited announced that they will report first half, 2025 results on Aug 28, 2025 Announcement • Jul 10
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Potassium Chloride and Sodium Chloride Injection (500Ml and 250Ml) from the National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Pot potassium Chloride and Sodium Chloride Injection (500ml and 250ml) from the National Medical Products Administration of China, both being the second of such approvals for the PRC entities, under type 4 chemical drug and regarded as passing the consistency evaluation. Pot potassium Chloride and sodium Chloride Injection is mainly used for the treatment and prevention of hypokalemia, and for the treatment of frequent multifocal premature heart beat or tachycardia caused by digitalis poisoning. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Announcement • Jul 08
SSY Group Limited Announces Update on Innovative Drug Development The board of directors of SSY Group Limited announce the updates on innovative drug development of the Group as follows: Progress on SYN045 tablets: As stated in the Company's announcement dated 3 April 2025, the Group's SYN045 tablets, a Type 1 new drug of chemical drug (a highly selective PGI2 receptor agonist with obvious anti-pulmonary hypertension effects on animals), has obtained approval from the National Medical Products Administration of China for adding three different specifications (10mg, 25mg and 50mg) for Phase I clinical trial. The Board announced that, recently, clinical trial of single administration of SYN045 tablets in 50mg and 100mg specifications and multiple administration of 25mg specifications have been completed. The research has shown good results in human pharmacokinetic characteristics and, as compared with drugs of the same drug target, significant improvements in safety and tolerability which are favourable in achieving long-term oral administration. As of now, a total of 18 invention patents has been submitted for SYN045 project, including 5 international invention patents (submitted for international pct applications) and 13 domestic invention patents (in which 5 invention patents related to compounds, crystal forms, preparations, etc. have been granted). Depending on the final results of the Phase I clinical trial, the Group is planning to commence the Phase IIa clinical trial in order to determine the dose-response relationship in the human body and explore the efficacy and safety in the body of patients. The Company will issue an announcement regarding the SYN045 tablets development as and when appropriate in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ‘Listing Rules’). Progress on other new drug development: The Board is also announced the updates on other new drug development of the Group as follows: Anti-epileptic innovative drug: Being a Type 1 anti-epileptic innovative drug project self-developed by the Group, its drug target is the potassium ion channel KCN Second Quarter /3. Currently, compound screening is commencing, and toxicity assessment is under preparation. Pain treatment innovative drug: Being a Type 1 innovative drug project self-developed by the Group for anti-diabetic peripheral neuropathic pain, its drug target is the adaptor-associated protein kinase 1 (AAK1). Currently, compound screening is commencing. New improved drug: The Group is currently commencing the research on improved formulations of three new drugs, two of which have been completed pharmacokinetic-based prescription studies and the remaining one is planned to submit an Investigational new drug (IND) application this year. With the plan of accelerating the innovative drug development and the progression of the above innovative drug projects, the Company will issue an announcement regarding the innovative drug development as and when appropriate in accordance with the Listing Rules. Announcement • Jul 03
SSY Group Limited Obtains Approval for Drug Production and Registration for Paracetamol Granules The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Paracetamol Granules (0.1g each bag) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Paracetamol Granule is a drug for children of which the Group has obtained the exclusive approval among the PRC entities. It is mainly used for fever caused by common cold or influenza in children, and also for relief of mild to moderate pain. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Announcement • Jun 13
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tranexamic Acid and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Tranexamic Acid and sodium Chloride Injection is mainly used for the treatment of all kinds of bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. Announcement • Jun 05
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Calcium Gluconate and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Cal calcium Gluconate and sodium Chloride Injection is mainly used for the treatment of acute hypocalcemia, magnesium poisoning and fluoride poisoning. Buy Or Sell Opportunity • May 30
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.3% to HK$2.93. The fair value is estimated to be HK$3.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 9.8% per annum over the same time period. Announcement • May 30
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Low Calcium Peritoneal Dialysis Solution (Lactate -G4.25%) (2000ml, with 4.25% glucose). Low Calcium Peritoneal dialysis Solution (Lactate-G4.25%) is mainly used for patients with acute or chronic renal failure who need continuous ambulatory peritoneal dialysis treatment due to ineffective non-dialysis treatment. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Upcoming Dividend • May 13
Upcoming dividend of HK$0.095 per share Eligible shareholders must have bought the stock before 20 May 2025. Payment date: 03 June 2025. Payout ratio is a comfortable 49% but the company is not cash flow positive. Trailing yield: 6.0%. Lower than top quartile of Hong Kong dividend payers (7.7%). Higher than average of industry peers (2.9%). Announcement • Apr 23
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval s for drug production and registration for Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (I) (Dapagliflozin 10mg and Metformin Hydrochlorides 1,000mg) and Ibuprofen Arginine Granules (0.4g and 0.2g) from the National Medical Products Administration of China (the "NMPA"), both being under type 4 chemical drug and regarded as passing the consistency evaluation. Dapagliflozin & Metformin Hydrochloride Sustained-release Tablet (I) is mainly used for improving blood sugar control in adult patients with type 2 diabetes, and Ibuprofen Arinine Granule is mainly used for the following symptoms: toothache, dysmenorrhea, pain caused by trauma, joint and ligament pain, back pain, headache, neuralgia, and fever caused by influenza. The Board is also pleased to announce that the Group's Acipimox and Diprophylline have obtained the approvals for registration from the NMPA to become bulk drugs for the preparations on the market. Acipimox is mainly used in the treatment of hypertriglyceridemia and hypercholesterolemia, and Diprophylline is mainly used in The treatment of bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, etc. for relieving wheezing symptoms. Recent Insider Transactions • Apr 13
Chairman & CEO recently bought HK$2.4m worth of stock On the 11th of April, Jiguang Qu bought around 800k shares on-market at roughly HK$3.01 per share. This trade did not impact their existing holding. In the last 3 months, they made an even bigger purchase worth HK$4.7m. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$23m worth in shares. Announcement • Apr 10
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Felodipine has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Felodipine is mainly used for the treatment of mild to moderate essential hypertension and stable angina. As stated in the Company's announcement dated 30 March 2023, the Group's Felodipines/Felodipine II Sustained-release Controlled-release Tablets (5mg) have been selected in the tender of the National Centralised Medicines Procurement in the PRC. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Recent Insider Transactions • Apr 02
Chairman & CEO recently bought HK$4.7m worth of stock On the 1st of April, Jiguang Qu bought around 1m shares on-market at roughly HK$3.37 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$28m worth in shares. Announcement • Apr 01
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Arbidol Hydrochloride Tablets (50mg) from National Medical Products Administration of China, being under type 3 chemical drug, regarded as passing the consistency evaluation and the second of such approvals for the PRC entities. The Group also produces bulk drug of Arbidol Hydrochloride. Arbidol Hydrochloride Tablet is mainly used in the treatment of upper respiratory tract infections caused by influenza A and B viruses, Novel coronavirus pneumonia, and can be used in the treatment of infections caused by SARS coronavirus and avian influenza virus. Announcement • Mar 31
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicardipine Hydrochloride Injection (10ml: 10mg) in form of ampoule from the National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. Nicardipine hydrochloride Injection in form of ampoule is mainly used for emergency treatment of abnormal hypertension during surgery and for hypertensive emergencies. As stated in the Company's announcement dated 5 March 2025, the Group's Nicardipine Hydrochlorides bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Board also announced that the Group has obtained the approval for drug production and registration for Sodium Bicarbonate Injection (10ml: 0.42g) in form of ampoul from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Sodium Bicarbonate Injection in form of ampoule is mainly used in the treatment of metabolic acidosis, alkalinization of urine and intravenous intoxication by certain drugs. Declared Dividend • Mar 31
Final dividend of HK$0.095 announced Shareholders will receive a dividend of HK$0.095. Ex-date: 20th May 2025 Payment date: 3rd June 2025 Dividend yield will be 5.4%, which is higher than the industry average of 3.6%. Sustainability & Growth The dividend has increased by an average of 11% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 30
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: HK$0.36 (down from HK$0.44 in FY 2023). Revenue: HK$5.77b (down 11% from FY 2023). Net income: HK$1.06b (down 20% from FY 2023). Profit margin: 18% (down from 20% in FY 2023). The decrease in margin was driven by lower revenue. Post-clinical trial products Approved (during full year): 119 Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 15%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Mar 28
SSY Group Limited, Annual General Meeting, May 16, 2025 SSY Group Limited, Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: rooms 4902-03, 49th floor, central plaza, 18 harbour road, wanchai, Hong Kong Announcement • Mar 22
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Nimodipine has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nimodipine is a calcium channel blocker, which is mainly used for the treatment of ischemic cerebrovascular disease, migraine, sudden deafness, mild or moderate hypertension, and for the prevention of cerebral vasospasm caused by mild subarachnoid hemorrhage. Announcement • Mar 21
SSY Group Limited Obtains Approval for Drug Production and Registration for Voriconazole for Oral Suspension The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Voriconazole for Oral Suspension (45g:3g) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Voriconazole for Oral suspension in oral dosage form, can be used in child aged 2 years or above and adult patients, and is mainly used in the treatment of various fungal infections, including invasive aspergillosis, candidemia and serious infections caused by Candida, Scedosporium and Fusarium, and for the prevention of invasive fungal infections in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Announcement • Mar 18
SSY Group Limited to Report Fiscal Year 2024 Results on Mar 28, 2025 SSY Group Limited announced that they will report fiscal year 2024 results at 12:30 PM, China Standard Time on Mar 28, 2025 Announcement • Mar 14
SSY Group Limited Obtains Approval for Drug Production and Registration for Epinephrine Hydrochloride Injection (1Ml:1Mg) from the National Medical Products Administration of China SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Epinephrine Hydrochloride Injection (1ml:1mg) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Epinephrine hydrochloride Injection is the main rescue drug for cardiopulmonary resuscitation in cardiac arrest, and can be used in the treatment of severe dyspnea caused by bronchospasm, rapid relief of anaphylaxis triggered by substances such as drugs, and prolongation of action time for infiltration anesthesia drugs. As stated in the Company's announcement dated 27 June 2024, the Group's Epinephrine bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Announcement • Mar 05
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Nicardipine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nicardipine hydrochloride is mainly used for the treatment of hypertension. Announcement • Feb 25
SSY Group Limited Provides an Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tranexamic Acid Tablets (0.5g) from the National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Tranexamic Acid Tablet is mainly used for various kinds of bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Acipimox Capsules (0.25g) from the NMPA, being under type 4 chemical drug, regarded as passing the consistency evaluation and the fourth of such approvals for the PRC entities. Acipimox Capsule is mainly used for reducing triglyceride levels in patients who do not respond adequately to other treatments (such as statins or fibrates). Announcement • Feb 24
SSY Group Limited Provides Update on Product Development SSY Group Limited announced that the Group's Piribedil has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities. Piribedil is mainly used for the treatment of Parkinson's disease and circulatory disturbance. Announcement • Jan 20
Ssy Group Limited Obtains Approval for Drug Production and Registration for Composite Potassium Hydrogen Phosphate Injection (5Ml) from National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Composite Potassium Hydrogen Phosphate Injection (5ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug, regarded as passing the consistency evaluation and the first of such approval for the PRC entities. Composite Potassium Hydrogen Phosphate Injection is a compound preparation which is mainly used for correction of hypophosphatemia in adult and child patients and for parenteral nutrition in adult and child patients when enteral nutrition is impossible, insufficient or prohibited. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Vortioxetine Hydrobromide Tablets (5mg) from the NMPA, being under type 4 chemical drug and regarded as passing the consistency evaluation. Vortioxetine Hydrobromide Tablet is mainly used for the treatment of depression in adults. As stated in the Company's announcement dated 27 December 2023, the Group's Vortioxetine Hydrobromide bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Announcement • Jan 08
SSY Group Limited Obtains Approval for Drug Production and Registration for Vonoprazan Fumarate Tablets The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Vonoprazan Fumarate Tablets (20mg and 10mg) from National Medical Products Administration of China (the ‘NMPA’), being under type 4 chemical drug and regarded as passing the consistency evaluation. Vonoprazan Fumarate Tablet is mainly used for the treatment of reflux esophagitis. As stated in the Company's announcement dated 16 December 2024, the Group's Vonoprazan Fumarate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Announcement • Jan 06
Ssy Group Limited Announces That the Benidipine Hydrochloride Obtained Approval for Registration from National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group's Benidipine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Benidipine Hydrochloride is mainly used for the treatment of primary hypertension and angina pectoris. Announcement • Dec 30
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Nikethamide has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nikethamide is a central nervous system stimulant, which is mainly used for the treatment of central respiratory depression and respiratory depression of various causes. Announcement • Dec 16
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announce that the Group's Vonoprazan Fumarate has obtained the approval for registration from the National Medical Products Administration of China (the ‘NMPA’) to become a bulk drug for the preparations on the market. Vonoprazan Fumarate is mainly used for the treatment of reflux esophagitis. In addition, the Board is also announced that the Group's Dronedarone Hydrochloride has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities. Dronedarone Hydrochloride is an antiarrhythmic drug. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Announcement • Dec 02
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Compound Sodium Acetate and Glucose Injection (500ml and 200ml) from National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation, and was among the first three PRC manufacturers with approvals for such drug production. Compound sodium Acetate andGlucose Injection is mainly used in replenishing and maintaining water and electrolytes as well as supplying energy when oral administration is not possible or insufficient, and is the latest generation of sugar-containing sodium acetate balanced crystalloid. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Announcement • Nov 27
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Glycerol Fructose and Sodium Chloride Injection (250ml). Glycerol Fructose and Sodium Chloride Injection is mainly used for the treatment of acute or chronic intracranial pressure increase and cerebral edema which are caused by cerebrovascular disease, brain trauma, brain tumors, intracranial inflammation, etc. Recent Insider Transactions • Nov 20
Chairman & CEO recently bought HK$3.4m worth of stock On the 19th of November, Jiguang Qu bought around 900k shares on-market at roughly HK$3.77 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$4.8m. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$24m worth in shares. Price Target Changed • Nov 07
Price target increased by 14% to HK$6.38 Up from HK$5.58, the current price target is an average from 4 analysts. New target price is 62% above last closing price of HK$3.95. Stock is down 11% over the past year. The company is forecast to post earnings per share of HK$0.46 for next year compared to HK$0.44 last year. Announcement • Nov 05
SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg) The board of directors (the "Board") of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Phenylephrine Hydrochloride Injection (1ml:10mg) from National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and
regarded as passing the consistency evaluation. Phenylephrine Hydrochloride Injection is mainly used in maintaining blood pressure during treatment of shock and during anesthesia, and is also used in controlling paroxysmal supraventricular tachycardia. As stated in the Company's announcement dated 23 July 2024, the Group's Phenylephrine Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Announcement • Oct 21
SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Cycloserine Capsules (0.25g) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Cycloserine Capsule is mainly used for the treatment of active pulmonary tuberculosis and extrapulmonary tuberculosis which are caused by susceptible tuberculosis bacteria and after ineffective first-line anti-tuberculosis drug treatment. It can also be used for the treatment of acute urinary tract infections caused by susceptible gram-positive bacteria and gram-negative bacteria. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Lornoxicam for injection (8mg) from the NMPA, being under type 4 chemical drug and regarded as passing the consistency evaluation. Lornoxicam for injection is mainly used for the short-term treatment of adults' acute pain from mild to moderate level which are not suitable for oral drug administration. Announcement • Oct 14
SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China SSY Group Limited announce that the Group's Cisatracurium Besilate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Cisatracurium Besilate is a muscle relaxant which is mainly used for muscle tension, sedation, general anesthesia during tracheal intubation and as an auxiliary medication to general anesthesia. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to HK$4.46, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 10x in the Pharmaceuticals industry in Hong Kong. Total returns to shareholders of 31% over the past three years. Recent Insider Transactions • Sep 25
Chairman & CEO recently bought HK$4.8m worth of stock On the 24th of September, Jiguang Qu bought around 1m shares on-market at roughly HK$3.87 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$21m worth in shares. Announcement • Sep 09
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Nefopam Hydrochloride Injection (2ml: 20mg), being the first of such approval for the PRC entities. Nefopam Hydrochlorides Injection is mainly used for symptomatic treatment of acute pain, especially for postoperative pain. Recent Insider Transactions • Sep 04
Chairman & CEO recently bought HK$1.5m worth of stock On the 2nd of September, Jiguang Qu bought around 400k shares on-market at roughly HK$3.81 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$16m worth in shares. Major Estimate Revision • Sep 04
Consensus EPS estimates fall by 10% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from HK$7.58b to HK$7.01b. EPS estimate also fell from HK$0.528 per share to HK$0.473 per share. Net income forecast to grow 11% next year vs 16% growth forecast for Pharmaceuticals industry in Hong Kong. Consensus price target down from HK$6.23 to HK$5.58. Share price rose 4.5% to HK$3.93 over the past week. Price Target Changed • Sep 02
Price target decreased by 10% to HK$5.58 Down from HK$6.23, the current price target is an average from 3 analysts. New target price is 44% above last closing price of HK$3.88. Stock is down 10.0% over the past year. The company is forecast to post earnings per share of HK$0.47 for next year compared to HK$0.44 last year. Announcement • Sep 02
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicorandil Tablets (5mg) from National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. Nicorandil Tablet is mainly used in the treatment of angina. As stated in the Company's announcement dated 9 October 2023, the Group's Nicorandil bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Reported Earnings • Aug 31
First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023) First half 2024 results: EPS: HK$0.23 (up from HK$0.21 in 1H 2023). Revenue: HK$3.34b (flat on 1H 2023). Net income: HK$685.7m (up 7.4% from 1H 2023). Profit margin: 21% (up from 19% in 1H 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Declared Dividend • Aug 30
First half dividend increased to HK$0.08 Dividend of HK$0.08 is 14% higher than last year. Ex-date: 12th September 2024 Payment date: 27th September 2024 Dividend yield will be 4.7%, which is higher than the industry average of 3.6%. Sustainability & Growth Dividend is covered by earnings (22% earnings payout ratio) but not covered by cash flows (161% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Aug 16
SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024 SSY Group Limited announced that they will report first half, 2024 results on Aug 28, 2024 Announcement • Aug 07
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Entacapone, Levodopa and Carbidopa Tablets (II) (Entacapone 200mg, Levodopa 100mg, Carbidopa 25mg) and Fluvoxamine maleate Tablets (100mg) from the National Medical Products Administration of China (the "NMPA"), both being under type 4 chemical drug and regarded as passing the consistency evaluation, with Entacapone, LevODopa and Carbidopa TableTS (II) being the first of such approval for the PRC entities. Entacapone, Levomopa and Carbidopa Tablet (II) are mainly used in adult patients with Parkinson's disease who have end-of-dose motor function fluctuations that cannot be controlled by levodopa/dopa decarboxylase (DDC) inhibitor therapy, and Fluvoxamine maleates Tablets are mainly used in the treatment of depression and obsessive-compulsive disorder. As stated in the Company's announcement dated 27 September 2023, the Group's Entacapone bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Board also announced that the Group has obtained the approval for drug production and registration for Lipid Emulsion (10%)/Amino Acids (15) and Glucose (20%) Injection (1000ml and 1500ml) from the NMPA, both being under type 4 chemical Drug, regarded as passing the consistency evaluation and the second of such approvals for the PRC entities. This three-ch chambers-bag injection is mainly used for parenteral nutrition when enteral nutrition is not feasible, insufficient or prohibited. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to HK$3.69, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 8x in the Pharmaceuticals industry in Hong Kong. Total loss to shareholders of 20% over the past three years. Announcement • Jul 23
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Phenylephrine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Phenylephrine Hydrochloride is mainly used in the treatment of low blood pressure caused by vasodilation during anesthesia. Announcement • Jul 16
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Betahistine Mesilate Tablets (6mg) from National Medical Products Administration of China (the "NMPA"), being the first of such approval for the PRC entities, under type 4 chemical drug and regarded as passing the consistency evaluation. As stated in the Company's announcement dated 27 June 2024, the Group's Betahistine Mesilate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Betahistine Mesilate Tablet is mainly used in the treatment of dizziness and lightheadedness associated with Meniere's disease, Meniere's syndrome and vertigo. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Announcement • Jun 29
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Deferasirox has obtained the approval for registration from the National Medical Products Administration of China (the "NMPA") to become a bulk drug for the preparations on the market. Deferasirox is mainly used in patients with iron accumulation due to the need for long-term blood transfusions (such as thalassemia or other rare anemias patients). In addition, the Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Esmolol Hydrochloride Injection (10ml:0.1g) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Esmolol hydrochloride Injection is mainly used in supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.